Alarming Findings: Common Hospice Medications Linked to Higher Death Rates in Dementia Patients
A groundbreaking study has uncovered a disturbing trend: the use of benzodiazepines and antipsychotics in hospice patients with dementia may be doing more harm than good. But here's where it gets controversial: while these medications are often prescribed to manage symptoms like agitation and anxiety, they could be significantly increasing the risk of death within 180 days. This raises critical questions about current prescribing practices and the need for urgent reform.
The study, published in JAMA Network Open, analyzed data from over 100,000 nursing home residents with Alzheimer’s disease and related dementias (ADRD) who were newly enrolled in hospice care. Led by geriatric psychiatrist Lauren B. Gerlach, DO, MS, the research found that initiating benzodiazepines or antipsychotics in this population was associated with a staggering 41% and 16% increased risk of mortality, respectively. And this is the part most people miss: even after accounting for various factors, the link between these medications and higher death rates remained alarmingly consistent.
Historically, these drugs have been go-to options for managing challenging behaviors in dementia patients. However, their risks—such as falls, cognitive decline, and cardiovascular issues—have long been a concern. This study not only reinforces those worries but also highlights the urgent need for dementia-specific hospice prescribing guidelines. Here’s the kicker: patients with ADRD in hospice are three times more likely to receive these medications compared to those not in hospice, making this issue even more pressing.
The researchers meticulously controlled for potential biases, excluding patients with extensive inpatient stays or those who received the medications only in their final days. They also found that each additional prescription fill was linked to a higher risk of death, suggesting a dose-dependent relationship. But here’s the question that’s sparking debate: Are we prioritizing symptom management over patient safety? And if so, what alternatives should we be investing in?
Nonpharmacologic approaches, such as behavioral interventions and environmental modifications, could offer safer solutions. However, these methods often require more time, resources, and training—something many hospice settings lack. The study’s authors argue that Medicare policy reforms are needed to track medication use and promote safer practices. They also call for national guidelines to reduce unwarranted variation in prescribing, ensuring that decisions are based on clinical evidence rather than agency norms.
What do you think? Is it time to rethink how we manage symptoms in dementia patients? Should we prioritize nonpharmacologic alternatives, even if they’re more resource-intensive? Share your thoughts in the comments—this is a conversation we can’t afford to ignore.
